Neoleukin Therapeutics (NGNE) P/E (2014 - 2026)
Neoleukin Therapeutics (NGNE) P/E from Mar 31, 2014 to Jul 21, 2026. The TTM Neoleukin Therapeutics (NGNE) P/E is -5.61. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Neoleukin Therapeutics (NGNE)
| Year | P/E | Change |
|---|---|---|
| 2026 | -5.61 | +65.43% |
| 2025 | -3.39 | -16.83% |
| 2024 | -4.08 | -3.50% |
| 2023 | -4.23 | +131.41% |
| 2022 | -1.83 | -89.16% |
| 2021 | -16.84 | -80.14% |
| 2020 | -84.77 | +58.48% |
| 2019 | -53.49 | +565.07% |
| 2018 | -8.04 | -73.66% |
| 2017 | -30.53 | -37.13% |
| 2016 | -48.56 | +29.32% |
| 2015 | -37.55 | +110.29% |
| 2014 | -17.86 | N/A |
Comparison Neoleukin Therapeutics (NGNE) P/E with competitors
Neoleukin Therapeutics (NGNE) P/E is -5.61.